| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Technology Assessment, Biomedical | 28 | 2024 | 307 | 5.930 |
Why?
|
| Cost-Benefit Analysis | 78 | 2024 | 5493 | 4.800 |
Why?
|
| Decision Support Techniques | 32 | 2020 | 1998 | 3.650 |
Why?
|
| Quality-Adjusted Life Years | 40 | 2024 | 1722 | 3.420 |
Why?
|
| Austria | 33 | 2024 | 207 | 2.830 |
Why?
|
| Early Detection of Cancer | 18 | 2023 | 3201 | 2.660 |
Why?
|
| Markov Chains | 32 | 2024 | 966 | 2.530 |
Why?
|
| Germany | 46 | 2024 | 875 | 2.200 |
Why?
|
| Mining | 9 | 2020 | 93 | 1.970 |
Why?
|
| Comparative Effectiveness Research | 10 | 2019 | 709 | 1.950 |
Why?
|
| Mass Screening | 23 | 2023 | 5429 | 1.780 |
Why?
|
| Mistletoe | 2 | 2023 | 2 | 1.720 |
Why?
|
| Viscum album | 2 | 2023 | 4 | 1.710 |
Why?
|
| Models, Economic | 11 | 2021 | 716 | 1.670 |
Why?
|
| Equipment and Supplies | 4 | 2022 | 273 | 1.570 |
Why?
|
| Models, Theoretical | 14 | 2021 | 3575 | 1.480 |
Why?
|
| Decision Making | 21 | 2017 | 3929 | 1.460 |
Why?
|
| Iodine | 4 | 2020 | 288 | 1.450 |
Why?
|
| Mercury | 8 | 2020 | 290 | 1.410 |
Why?
|
| Hepatitis C, Chronic | 11 | 2019 | 1032 | 1.350 |
Why?
|
| Quality of Life | 31 | 2024 | 13367 | 1.270 |
Why?
|
| Gold | 9 | 2020 | 482 | 1.220 |
Why?
|
| Policy Making | 3 | 2022 | 542 | 1.140 |
Why?
|
| Breast Neoplasms | 15 | 2023 | 21019 | 1.110 |
Why?
|
| Ribavirin | 8 | 2019 | 395 | 1.080 |
Why?
|
| Health Care Costs | 23 | 2021 | 3242 | 1.060 |
Why?
|
| Antiviral Agents | 11 | 2019 | 3060 | 1.060 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2015 | 686 | 1.050 |
Why?
|
| Uterine Cervical Neoplasms | 8 | 2022 | 2020 | 1.050 |
Why?
|
| Models, Statistical | 13 | 2022 | 5079 | 1.030 |
Why?
|
| Status Epilepticus | 3 | 2020 | 460 | 1.010 |
Why?
|
| Porpoises | 3 | 2020 | 4 | 0.980 |
Why?
|
| Ovarian Neoplasms | 4 | 2023 | 4878 | 0.960 |
Why?
|
| Interferon-alpha | 8 | 2019 | 921 | 0.940 |
Why?
|
| Risk Management | 2 | 2024 | 558 | 0.940 |
Why?
|
| Humans | 314 | 2024 | 761596 | 0.920 |
Why?
|
| Myelodysplastic Syndromes | 6 | 2023 | 1394 | 0.890 |
Why?
|
| Deficiency Diseases | 2 | 2020 | 74 | 0.880 |
Why?
|
| Fractional Flow Reserve, Myocardial | 7 | 2019 | 323 | 0.840 |
Why?
|
| Europe | 18 | 2024 | 3420 | 0.810 |
Why?
|
| Environmental Monitoring | 7 | 2020 | 1460 | 0.810 |
Why?
|
| Papillomavirus Infections | 6 | 2022 | 1613 | 0.810 |
Why?
|
| Leg Ulcer | 1 | 2021 | 71 | 0.750 |
Why?
|
| Evidence-Based Practice | 4 | 2017 | 495 | 0.740 |
Why?
|
| Randomized Controlled Trials as Topic | 19 | 2024 | 10212 | 0.740 |
Why?
|
| Coronary Angiography | 31 | 2019 | 4471 | 0.730 |
Why?
|
| Phocoena | 1 | 2020 | 2 | 0.730 |
Why?
|
| Uterine Cervical Dysplasia | 3 | 2022 | 384 | 0.730 |
Why?
|
| Guidelines as Topic | 9 | 2024 | 1386 | 0.720 |
Why?
|
| Mammography | 5 | 2017 | 2430 | 0.710 |
Why?
|
| Evidence-Based Medicine | 10 | 2022 | 3688 | 0.700 |
Why?
|
| Mercury Compounds | 2 | 2009 | 7 | 0.700 |
Why?
|
| Hepatitis C | 7 | 2009 | 1584 | 0.690 |
Why?
|
| Survival Analysis | 16 | 2020 | 10090 | 0.690 |
Why?
|
| Mercury Poisoning | 2 | 2009 | 32 | 0.690 |
Why?
|
| Troponin I | 1 | 2024 | 651 | 0.680 |
Why?
|
| Life Expectancy | 10 | 2020 | 1243 | 0.680 |
Why?
|
| Malus | 1 | 2020 | 50 | 0.670 |
Why?
|
| Uncertainty | 7 | 2022 | 754 | 0.670 |
Why?
|
| Hepacivirus | 4 | 2013 | 1336 | 0.660 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2023 | 621 | 0.650 |
Why?
|
| Computer Simulation | 8 | 2019 | 6241 | 0.650 |
Why?
|
| Thyroid Diseases | 2 | 2020 | 386 | 0.640 |
Why?
|
| Resistance Training | 4 | 2020 | 193 | 0.640 |
Why?
|
| Middle Aged | 131 | 2024 | 220921 | 0.630 |
Why?
|
| Coronary Artery Disease | 18 | 2019 | 6403 | 0.620 |
Why?
|
| Colorectal Neoplasms | 6 | 2023 | 6938 | 0.620 |
Why?
|
| Heart Failure | 14 | 2024 | 11671 | 0.610 |
Why?
|
| Aortic Aneurysm, Abdominal | 2 | 2023 | 1228 | 0.610 |
Why?
|
| Drug Substitution | 3 | 2016 | 290 | 0.610 |
Why?
|
| Female | 162 | 2024 | 392705 | 0.610 |
Why?
|
| Clinical Coding | 1 | 2019 | 181 | 0.600 |
Why?
|
| gamma-Glutamylcyclotransferase | 1 | 2017 | 11 | 0.600 |
Why?
|
| Economics, Pharmaceutical | 4 | 2020 | 87 | 0.600 |
Why?
|
| Budgets | 1 | 2019 | 230 | 0.580 |
Why?
|
| Dyspnea | 3 | 2021 | 1347 | 0.580 |
Why?
|
| Natriuretic Peptide, Brain | 3 | 2021 | 1723 | 0.580 |
Why?
|
| Polyethylene Glycols | 5 | 2012 | 1189 | 0.580 |
Why?
|
| Stroke | 7 | 2023 | 9758 | 0.570 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2022 | 395 | 0.560 |
Why?
|
| Cost of Illness | 9 | 2018 | 1937 | 0.550 |
Why?
|
| National Health Programs | 6 | 2020 | 440 | 0.550 |
Why?
|
| Aged | 100 | 2024 | 169310 | 0.550 |
Why?
|
| Research Design | 13 | 2024 | 6180 | 0.550 |
Why?
|
| Parkinson Disease | 13 | 2016 | 2877 | 0.510 |
Why?
|
| Medical Errors | 1 | 2024 | 1263 | 0.510 |
Why?
|
| Coronary Stenosis | 11 | 2006 | 794 | 0.510 |
Why?
|
| Selection Bias | 3 | 2019 | 359 | 0.510 |
Why?
|
| Preventive Health Services | 1 | 2020 | 567 | 0.510 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2019 | 3246 | 0.510 |
Why?
|
| Angioplasty, Balloon, Coronary | 16 | 2011 | 1725 | 0.510 |
Why?
|
| Blood Vessel Prosthesis Implantation | 7 | 2023 | 1428 | 0.500 |
Why?
|
| Immunization Programs | 2 | 2009 | 268 | 0.500 |
Why?
|
| Stents | 19 | 2011 | 3179 | 0.500 |
Why?
|
| Neoplasms | 9 | 2020 | 22173 | 0.490 |
Why?
|
| Noise, Transportation | 2 | 2020 | 56 | 0.480 |
Why?
|
| Adult | 87 | 2024 | 221210 | 0.480 |
Why?
|
| Vaginal Smears | 4 | 2020 | 499 | 0.480 |
Why?
|
| Advisory Committees | 4 | 2013 | 787 | 0.470 |
Why?
|
| Coronary Disease | 18 | 2011 | 5914 | 0.470 |
Why?
|
| Drug Industry | 3 | 2018 | 788 | 0.470 |
Why?
|
| Delivery of Health Care | 9 | 2022 | 5337 | 0.470 |
Why?
|
| Mortality | 4 | 2020 | 2902 | 0.460 |
Why?
|
| Cross-Cultural Comparison | 3 | 2011 | 635 | 0.460 |
Why?
|
| Risk Assessment | 24 | 2024 | 23996 | 0.460 |
Why?
|
| Quality Indicators, Health Care | 1 | 2024 | 1792 | 0.460 |
Why?
|
| Withholding Treatment | 1 | 2018 | 617 | 0.450 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2018 | 787 | 0.450 |
Why?
|
| International Classification of Diseases | 1 | 2019 | 910 | 0.450 |
Why?
|
| Male | 141 | 2024 | 360846 | 0.450 |
Why?
|
| Ultrasonography, Interventional | 16 | 2009 | 1496 | 0.450 |
Why?
|
| Expert Testimony | 1 | 2016 | 364 | 0.450 |
Why?
|
| Peptide Fragments | 3 | 2021 | 5112 | 0.440 |
Why?
|
| Coronary Restenosis | 10 | 2009 | 396 | 0.440 |
Why?
|
| Medical Order Entry Systems | 2 | 2009 | 521 | 0.430 |
Why?
|
| Work Capacity Evaluation | 1 | 2013 | 44 | 0.430 |
Why?
|
| Drugs, Generic | 2 | 2015 | 448 | 0.420 |
Why?
|
| Health Expenditures | 2 | 2016 | 2366 | 0.420 |
Why?
|
| Health Services Research | 2 | 2020 | 1812 | 0.410 |
Why?
|
| Methadone | 3 | 2024 | 321 | 0.410 |
Why?
|
| Data Collection | 7 | 2017 | 3322 | 0.410 |
Why?
|
| Sensitivity and Specificity | 30 | 2021 | 14665 | 0.410 |
Why?
|
| Internationality | 3 | 2015 | 1001 | 0.410 |
Why?
|
| Data Interpretation, Statistical | 7 | 2013 | 2691 | 0.410 |
Why?
|
| Diabetic Foot | 3 | 2024 | 380 | 0.410 |
Why?
|
| Cancer Care Facilities | 1 | 2015 | 422 | 0.400 |
Why?
|
| Occupational Exposure | 5 | 2017 | 1813 | 0.390 |
Why?
|
| Papillomavirus Vaccines | 2 | 2009 | 496 | 0.390 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2012 | 146 | 0.390 |
Why?
|
| Tissue Scaffolds | 1 | 2018 | 934 | 0.390 |
Why?
|
| Loneliness | 2 | 2024 | 203 | 0.390 |
Why?
|
| Occult Blood | 5 | 2023 | 198 | 0.390 |
Why?
|
| Veterans Health | 1 | 2013 | 215 | 0.380 |
Why?
|
| Treatment Outcome | 43 | 2024 | 64685 | 0.370 |
Why?
|
| Financing, Personal | 1 | 2013 | 309 | 0.360 |
Why?
|
| Phytotherapy | 2 | 2023 | 296 | 0.360 |
Why?
|
| Antiparkinson Agents | 6 | 2016 | 184 | 0.360 |
Why?
|
| Population Surveillance | 2 | 2018 | 2598 | 0.360 |
Why?
|
| Perinatal Mortality | 1 | 2011 | 101 | 0.350 |
Why?
|
| Hazardous Substances | 1 | 2011 | 153 | 0.350 |
Why?
|
| Decision Trees | 2 | 2021 | 504 | 0.350 |
Why?
|
| Abdominal Fat | 1 | 2012 | 221 | 0.350 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 3 | 2022 | 3204 | 0.340 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2011 | 190 | 0.340 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2024 | 5314 | 0.340 |
Why?
|
| Disease Management | 5 | 2024 | 2508 | 0.340 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2015 | 5672 | 0.330 |
Why?
|
| Cooperative Behavior | 5 | 2015 | 1505 | 0.330 |
Why?
|
| Program Evaluation | 5 | 2020 | 2495 | 0.330 |
Why?
|
| Ambulatory Care Facilities | 3 | 2013 | 935 | 0.330 |
Why?
|
| Colonoscopy | 5 | 2023 | 1394 | 0.330 |
Why?
|
| Endovascular Procedures | 1 | 2023 | 2183 | 0.320 |
Why?
|
| Coronary Circulation | 10 | 2005 | 1569 | 0.320 |
Why?
|
| Cardiovascular Diseases | 5 | 2024 | 15502 | 0.320 |
Why?
|
| Registries | 12 | 2020 | 8225 | 0.320 |
Why?
|
| Economics, Medical | 5 | 2023 | 112 | 0.320 |
Why?
|
| Obesity, Abdominal | 1 | 2012 | 374 | 0.310 |
Why?
|
| Zimbabwe | 4 | 2020 | 135 | 0.310 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2021 | 11742 | 0.310 |
Why?
|
| Aircraft | 1 | 2009 | 130 | 0.310 |
Why?
|
| Alphapapillomavirus | 2 | 2022 | 218 | 0.310 |
Why?
|
| Simvastatin | 1 | 2011 | 346 | 0.310 |
Why?
|
| Prostatic Neoplasms | 6 | 2017 | 11122 | 0.310 |
Why?
|
| Environmental Pollutants | 4 | 2023 | 1277 | 0.300 |
Why?
|
| Quarantine | 2 | 2020 | 181 | 0.300 |
Why?
|
| Opioid-Related Disorders | 4 | 2024 | 2164 | 0.300 |
Why?
|
| Aged, 80 and over | 32 | 2024 | 58984 | 0.300 |
Why?
|
| Seals, Earless | 3 | 2020 | 12 | 0.300 |
Why?
|
| Health Care Rationing | 3 | 2010 | 437 | 0.290 |
Why?
|
| Electronic Prescribing | 1 | 2008 | 114 | 0.280 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 1520 | 0.280 |
Why?
|
| Health Policy | 9 | 2014 | 2684 | 0.280 |
Why?
|
| Marketing of Health Services | 1 | 2008 | 151 | 0.280 |
Why?
|
| Air Pollutants, Occupational | 1 | 2009 | 407 | 0.280 |
Why?
|
| Canada | 5 | 2022 | 2122 | 0.280 |
Why?
|
| Probability | 5 | 2021 | 2477 | 0.280 |
Why?
|
| Ambulatory Care | 5 | 2013 | 2775 | 0.270 |
Why?
|
| Hair | 7 | 2017 | 498 | 0.270 |
Why?
|
| Antineoplastic Agents | 7 | 2024 | 13642 | 0.270 |
Why?
|
| Myocardial Infarction | 8 | 2018 | 11461 | 0.270 |
Why?
|
| Severity of Illness Index | 16 | 2020 | 15843 | 0.270 |
Why?
|
| Human papillomavirus 18 | 1 | 2007 | 125 | 0.270 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2017 | 1413 | 0.260 |
Why?
|
| Incidence | 17 | 2021 | 21355 | 0.260 |
Why?
|
| Causality | 4 | 2022 | 1242 | 0.260 |
Why?
|
| Quality of Health Care | 2 | 2019 | 4331 | 0.260 |
Why?
|
| Liver Neoplasms | 5 | 2020 | 4317 | 0.260 |
Why?
|
| Hospitalization | 10 | 2022 | 10721 | 0.260 |
Why?
|
| Patient Satisfaction | 3 | 2021 | 3462 | 0.260 |
Why?
|
| Neurologic Examination | 3 | 2009 | 916 | 0.260 |
Why?
|
| Drug Therapy, Combination | 7 | 2019 | 6312 | 0.260 |
Why?
|
| Mothers | 2 | 2020 | 2198 | 0.250 |
Why?
|
| Anthracyclines | 1 | 2008 | 284 | 0.250 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2020 | 2422 | 0.250 |
Why?
|
| Sample Size | 2 | 2020 | 841 | 0.250 |
Why?
|
| Human papillomavirus 16 | 1 | 2007 | 267 | 0.250 |
Why?
|
| Opiate Substitution Treatment | 3 | 2024 | 444 | 0.250 |
Why?
|
| Secondary Prevention | 2 | 2011 | 1475 | 0.250 |
Why?
|
| Coronary Vessels | 10 | 2009 | 3096 | 0.240 |
Why?
|
| Hospitals, University | 3 | 2024 | 564 | 0.240 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 3 | 2005 | 1068 | 0.240 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2014 | 2425 | 0.240 |
Why?
|
| Assisted Living Facilities | 1 | 2024 | 27 | 0.240 |
Why?
|
| Australia | 3 | 2020 | 1250 | 0.240 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2018 | 3627 | 0.230 |
Why?
|
| Taxoids | 1 | 2008 | 668 | 0.230 |
Why?
|
| Brachytherapy | 7 | 2005 | 1223 | 0.230 |
Why?
|
| Emigrants and Immigrants | 1 | 2011 | 543 | 0.230 |
Why?
|
| Indonesia | 4 | 2016 | 128 | 0.230 |
Why?
|
| Risk Factors | 28 | 2023 | 74213 | 0.230 |
Why?
|
| Tuberculosis, Meningeal | 1 | 2024 | 47 | 0.230 |
Why?
|
| Benchmarking | 3 | 2018 | 1045 | 0.230 |
Why?
|
| Colitis, Ulcerative | 2 | 2013 | 1922 | 0.230 |
Why?
|
| Dihydroxyphenylalanine | 1 | 2003 | 74 | 0.220 |
Why?
|
| Cross-Sectional Studies | 11 | 2023 | 26129 | 0.220 |
Why?
|
| Mercury Poisoning, Nervous System | 2 | 2017 | 8 | 0.220 |
Why?
|
| Body Burden | 4 | 2017 | 158 | 0.220 |
Why?
|
| Common Dolphins | 1 | 2023 | 1 | 0.220 |
Why?
|
| Crohn Disease | 2 | 2013 | 2279 | 0.220 |
Why?
|
| Bottle-Nosed Dolphin | 1 | 2023 | 2 | 0.220 |
Why?
|
| Aesculus | 1 | 2002 | 2 | 0.220 |
Why?
|
| C-Reactive Protein | 3 | 2010 | 3826 | 0.210 |
Why?
|
| Disabled Persons | 1 | 2013 | 1226 | 0.210 |
Why?
|
| Liver Cirrhosis | 3 | 2012 | 1935 | 0.210 |
Why?
|
| Oceans and Seas | 2 | 2020 | 47 | 0.210 |
Why?
|
| Algorithms | 6 | 2022 | 14033 | 0.210 |
Why?
|
| Mycoplasma Infections | 1 | 2023 | 120 | 0.210 |
Why?
|
| Delphi Technique | 3 | 2022 | 846 | 0.210 |
Why?
|
| Hospitals, Public | 1 | 2024 | 202 | 0.210 |
Why?
|
| Disease Progression | 14 | 2017 | 13510 | 0.210 |
Why?
|
| Adenoma | 2 | 2023 | 2163 | 0.210 |
Why?
|
| Indoles | 1 | 2011 | 1833 | 0.210 |
Why?
|
| Drug and Narcotic Control | 1 | 2023 | 144 | 0.210 |
Why?
|
| Costs and Cost Analysis | 8 | 2022 | 1668 | 0.210 |
Why?
|
| Anemia | 2 | 2022 | 1509 | 0.200 |
Why?
|
| Body Composition | 1 | 2012 | 2426 | 0.200 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2023 | 138 | 0.200 |
Why?
|
| Emergency Service, Hospital | 2 | 2021 | 7879 | 0.200 |
Why?
|
| Seeds | 1 | 2002 | 122 | 0.200 |
Why?
|
| Brazil | 3 | 2024 | 1230 | 0.200 |
Why?
|
| Plant Preparations | 1 | 2002 | 94 | 0.200 |
Why?
|
| Muscle, Skeletal | 2 | 2020 | 4948 | 0.200 |
Why?
|
| Prognosis | 15 | 2020 | 29629 | 0.200 |
Why?
|
| Medication Errors | 1 | 2008 | 783 | 0.200 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2017 | 9280 | 0.200 |
Why?
|
| Decision Support Systems, Clinical | 3 | 2018 | 1175 | 0.200 |
Why?
|
| Food Contamination | 2 | 2016 | 191 | 0.200 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2022 | 1390 | 0.200 |
Why?
|
| Heart Defects, Congenital | 1 | 2018 | 4671 | 0.190 |
Why?
|
| Medical Informatics | 1 | 2009 | 733 | 0.190 |
Why?
|
| Phoca | 1 | 2021 | 7 | 0.190 |
Why?
|
| Environmental Exposure | 5 | 2020 | 4485 | 0.190 |
Why?
|
| Parasitic Diseases, Animal | 1 | 2001 | 5 | 0.190 |
Why?
|
| Venous Insufficiency | 1 | 2002 | 108 | 0.190 |
Why?
|
| Eagles | 1 | 2020 | 4 | 0.190 |
Why?
|
| Databases, Factual | 7 | 2020 | 7968 | 0.190 |
Why?
|
| Patient Preference | 2 | 2020 | 927 | 0.190 |
Why?
|
| Myocardial Revascularization | 1 | 2005 | 790 | 0.180 |
Why?
|
| Latvia | 1 | 2020 | 14 | 0.180 |
Why?
|
| Angina, Unstable | 3 | 2011 | 888 | 0.180 |
Why?
|
| Clinical Protocols | 1 | 2006 | 1440 | 0.180 |
Why?
|
| Milk, Human | 2 | 2020 | 486 | 0.180 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2010 | 2048 | 0.180 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2017 | 3514 | 0.180 |
Why?
|
| Heart Transplantation | 9 | 2008 | 3233 | 0.180 |
Why?
|
| Ischemic Attack, Transient | 2 | 2022 | 882 | 0.180 |
Why?
|
| Human Activities | 1 | 2020 | 26 | 0.180 |
Why?
|
| Proportional Hazards Models | 8 | 2024 | 12463 | 0.180 |
Why?
|
| Asia | 2 | 2020 | 619 | 0.170 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2003 | 396 | 0.170 |
Why?
|
| Poland | 1 | 2020 | 198 | 0.170 |
Why?
|
| Evaluation Studies as Topic | 3 | 2012 | 1625 | 0.170 |
Why?
|
| Manipulation, Spinal | 1 | 2000 | 21 | 0.170 |
Why?
|
| Public Health | 3 | 2023 | 2669 | 0.170 |
Why?
|
| Exercise Test | 1 | 2008 | 2127 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 3 | 2013 | 9177 | 0.170 |
Why?
|
| Combined Modality Therapy | 7 | 2020 | 8527 | 0.170 |
Why?
|
| Patient Access to Records | 1 | 2021 | 119 | 0.170 |
Why?
|
| Diabetes Mellitus | 4 | 2022 | 5841 | 0.170 |
Why?
|
| Recombinant Proteins | 6 | 2009 | 6534 | 0.170 |
Why?
|
| Narcotic Antagonists | 1 | 2024 | 585 | 0.170 |
Why?
|
| Motorcycles | 1 | 2020 | 42 | 0.170 |
Why?
|
| Judgment | 1 | 2022 | 273 | 0.170 |
Why?
|
| Guanine | 2 | 2011 | 279 | 0.170 |
Why?
|
| Glutamates | 2 | 2011 | 389 | 0.170 |
Why?
|
| Sick Leave | 1 | 2020 | 105 | 0.170 |
Why?
|
| Bandages | 1 | 2021 | 269 | 0.170 |
Why?
|
| Industry | 1 | 2001 | 364 | 0.170 |
Why?
|
| Interdisciplinary Communication | 2 | 2015 | 931 | 0.170 |
Why?
|
| Plant Extracts | 1 | 2023 | 497 | 0.170 |
Why?
|
| Policy | 3 | 2021 | 509 | 0.170 |
Why?
|
| Cohort Studies | 16 | 2024 | 41495 | 0.160 |
Why?
|
| Health Priorities | 1 | 2002 | 374 | 0.160 |
Why?
|
| Consensus | 3 | 2020 | 3124 | 0.160 |
Why?
|
| Prevalence | 12 | 2023 | 15733 | 0.160 |
Why?
|
| Pharmacogenetics | 3 | 2012 | 675 | 0.160 |
Why?
|
| Predictive Value of Tests | 13 | 2020 | 15266 | 0.160 |
Why?
|
| Health Status | 5 | 2023 | 4077 | 0.160 |
Why?
|
| Regression Analysis | 9 | 2021 | 6345 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 7 | 2020 | 7391 | 0.160 |
Why?
|
| Insurance, Health, Reimbursement | 2 | 2012 | 385 | 0.160 |
Why?
|
| Respiration Disorders | 1 | 2022 | 367 | 0.160 |
Why?
|
| Contact Tracing | 1 | 2021 | 271 | 0.160 |
Why?
|
| Public Policy | 1 | 2023 | 559 | 0.160 |
Why?
|
| Drug Resistance, Viral | 1 | 2004 | 862 | 0.160 |
Why?
|
| Young Adult | 14 | 2024 | 59260 | 0.160 |
Why?
|
| Health Services | 2 | 2022 | 752 | 0.160 |
Why?
|
| Systems Analysis | 1 | 2019 | 169 | 0.160 |
Why?
|
| British Columbia | 3 | 2024 | 241 | 0.150 |
Why?
|
| Follow-Up Studies | 29 | 2024 | 39106 | 0.150 |
Why?
|
| Diagnostic Imaging | 2 | 2010 | 3530 | 0.150 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2020 | 293 | 0.150 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2004 | 2199 | 0.150 |
Why?
|
| North America | 2 | 2020 | 1276 | 0.150 |
Why?
|
| Denmark | 1 | 2020 | 771 | 0.150 |
Why?
|
| Stereotaxic Techniques | 1 | 2020 | 555 | 0.150 |
Why?
|
| Membrane Transport Proteins | 1 | 2003 | 1035 | 0.150 |
Why?
|
| Time Factors | 21 | 2024 | 39969 | 0.150 |
Why?
|
| Ki-67 Antigen | 1 | 2020 | 629 | 0.150 |
Why?
|
| Africa | 1 | 2020 | 709 | 0.140 |
Why?
|
| Proline | 1 | 2019 | 457 | 0.140 |
Why?
|
| Tanzania | 3 | 2011 | 1390 | 0.140 |
Why?
|
| Clinical Trials as Topic | 4 | 2022 | 8002 | 0.140 |
Why?
|
| Efficiency | 1 | 2020 | 476 | 0.140 |
Why?
|
| Carotid Artery Diseases | 1 | 2023 | 877 | 0.140 |
Why?
|
| Pancreatectomy | 1 | 2021 | 811 | 0.140 |
Why?
|
| Chronic Disease | 7 | 2024 | 9319 | 0.140 |
Why?
|
| Retrospective Studies | 13 | 2024 | 80647 | 0.140 |
Why?
|
| Heart Diseases | 4 | 2024 | 2781 | 0.140 |
Why?
|
| Genetic Testing | 2 | 2022 | 3537 | 0.140 |
Why?
|
| Disease-Free Survival | 5 | 2011 | 6815 | 0.140 |
Why?
|
| Phenylurea Compounds | 1 | 2020 | 529 | 0.140 |
Why?
|
| Neoplasm Staging | 5 | 2017 | 11120 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2020 | 698 | 0.140 |
Why?
|
| HIV | 1 | 2004 | 1582 | 0.140 |
Why?
|
| Prospective Studies | 33 | 2022 | 54423 | 0.130 |
Why?
|
| Multivariate Analysis | 9 | 2020 | 12059 | 0.130 |
Why?
|
| Deep Brain Stimulation | 2 | 2016 | 832 | 0.130 |
Why?
|
| Medical History Taking | 1 | 2020 | 774 | 0.130 |
Why?
|
| Dengue | 1 | 2019 | 254 | 0.130 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2018 | 273 | 0.130 |
Why?
|
| Biomedical Research | 4 | 2018 | 3429 | 0.130 |
Why?
|
| Oligopeptides | 2 | 2019 | 1187 | 0.130 |
Why?
|
| Government Regulation | 1 | 2020 | 524 | 0.130 |
Why?
|
| Lung Neoplasms | 3 | 2024 | 13381 | 0.130 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2004 | 1897 | 0.130 |
Why?
|
| Muscle Strength | 1 | 2020 | 624 | 0.130 |
Why?
|
| Survival Rate | 7 | 2016 | 12723 | 0.130 |
Why?
|
| Efficiency, Organizational | 2 | 2010 | 695 | 0.130 |
Why?
|
| Health Services Needs and Demand | 2 | 2021 | 1403 | 0.130 |
Why?
|
| Adolescent | 18 | 2023 | 88326 | 0.130 |
Why?
|
| Insurance Claim Review | 1 | 2020 | 741 | 0.130 |
Why?
|
| Vitamins | 2 | 2022 | 1635 | 0.130 |
Why?
|
| Likelihood Functions | 2 | 2013 | 992 | 0.130 |
Why?
|
| Cholecalciferol | 1 | 2020 | 553 | 0.130 |
Why?
|
| Switzerland | 2 | 2013 | 324 | 0.130 |
Why?
|
| Activities of Daily Living | 3 | 2022 | 2421 | 0.130 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2023 | 1048 | 0.130 |
Why?
|
| Cost Savings | 1 | 2021 | 913 | 0.130 |
Why?
|
| Testicular Neoplasms | 1 | 2021 | 799 | 0.120 |
Why?
|
| Comorbidity | 5 | 2023 | 10508 | 0.120 |
Why?
|
| Philosophy, Medical | 1 | 2015 | 79 | 0.120 |
Why?
|
| Mountaineering | 1 | 2015 | 45 | 0.120 |
Why?
|
| Databases, Bibliographic | 1 | 2015 | 130 | 0.120 |
Why?
|
| Drug-Eluting Stents | 3 | 2010 | 681 | 0.120 |
Why?
|
| Age Factors | 7 | 2017 | 18399 | 0.120 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2020 | 2297 | 0.120 |
Why?
|
| Insurance, Health | 4 | 2020 | 2499 | 0.120 |
Why?
|
| Mastectomy | 1 | 2023 | 1822 | 0.120 |
Why?
|
| Angiography, Digital Subtraction | 3 | 2005 | 335 | 0.120 |
Why?
|
| Troponin | 1 | 2018 | 502 | 0.120 |
Why?
|
| Decision Making, Organizational | 1 | 2015 | 136 | 0.120 |
Why?
|
| Cisplatin | 2 | 2011 | 1652 | 0.120 |
Why?
|
| Spinal Diseases | 1 | 2000 | 564 | 0.120 |
Why?
|
| Virus Diseases | 1 | 2001 | 718 | 0.120 |
Why?
|
| Malnutrition | 1 | 2021 | 645 | 0.120 |
Why?
|
| Minke Whale | 1 | 2014 | 1 | 0.120 |
Why?
|
| Influenza Vaccines | 1 | 2022 | 768 | 0.120 |
Why?
|
| Reproducibility of Results | 11 | 2019 | 20100 | 0.120 |
Why?
|
| Morbidity | 3 | 2021 | 1752 | 0.120 |
Why?
|
| Quinolines | 1 | 2020 | 765 | 0.120 |
Why?
|
| Needs Assessment | 1 | 2020 | 1139 | 0.120 |
Why?
|
| Acute Disease | 4 | 2021 | 7237 | 0.120 |
Why?
|
| Altitude Sickness | 1 | 2015 | 91 | 0.120 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2006 | 1432 | 0.120 |
Why?
|
| Cattle | 2 | 2018 | 3849 | 0.120 |
Why?
|
| Infant, Newborn | 7 | 2022 | 26202 | 0.110 |
Why?
|
| Altitude | 1 | 2015 | 163 | 0.110 |
Why?
|
| Accidental Falls | 1 | 2022 | 1068 | 0.110 |
Why?
|
| Pericardium | 1 | 2018 | 675 | 0.110 |
Why?
|
| Movement | 1 | 2021 | 1478 | 0.110 |
Why?
|
| Therapeutic Equivalency | 1 | 2014 | 134 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2011 | 6345 | 0.110 |
Why?
|
| Telephone | 1 | 2017 | 627 | 0.110 |
Why?
|
| Politics | 1 | 2020 | 815 | 0.110 |
Why?
|
| Patient Participation | 2 | 2021 | 1445 | 0.110 |
Why?
|
| Echocardiography, Stress | 2 | 2005 | 134 | 0.110 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2013 | 52 | 0.110 |
Why?
|
| Reoperation | 3 | 2018 | 4303 | 0.110 |
Why?
|
| Hand Strength | 1 | 2016 | 456 | 0.110 |
Why?
|
| Tremor | 2 | 2017 | 191 | 0.110 |
Why?
|
| Subthalamic Nucleus | 1 | 2016 | 195 | 0.110 |
Why?
|
| Sleep | 1 | 2009 | 4768 | 0.110 |
Why?
|
| Cervical Vertebrae | 1 | 2000 | 980 | 0.110 |
Why?
|
| Genetic Counseling | 1 | 2017 | 627 | 0.110 |
Why?
|
| Occupational Diseases | 1 | 2001 | 1490 | 0.110 |
Why?
|
| Cetacea | 1 | 2012 | 5 | 0.110 |
Why?
|
| Narcolepsy | 2 | 2007 | 199 | 0.110 |
Why?
|
| Socioeconomic Factors | 3 | 2020 | 7828 | 0.110 |
Why?
|
| Hospice Care | 1 | 2020 | 678 | 0.110 |
Why?
|
| Watchful Waiting | 1 | 2017 | 491 | 0.110 |
Why?
|
| Tunica Intima | 3 | 2008 | 459 | 0.110 |
Why?
|
| Physical Examination | 1 | 2019 | 1255 | 0.110 |
Why?
|
| Exercise | 3 | 2020 | 5890 | 0.110 |
Why?
|
| Behavior, Animal | 1 | 2021 | 1878 | 0.110 |
Why?
|
| Infant | 5 | 2020 | 36193 | 0.100 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 2079 | 0.100 |
Why?
|
| Administrative Personnel | 1 | 2014 | 184 | 0.100 |
Why?
|
| Body Weight | 1 | 2003 | 4618 | 0.100 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 3701 | 0.100 |
Why?
|
| Graft Occlusion, Vascular | 3 | 2004 | 537 | 0.100 |
Why?
|
| Bacterial Infections | 1 | 2001 | 1391 | 0.100 |
Why?
|
| Buprenorphine | 1 | 2020 | 656 | 0.100 |
Why?
|
| Inpatients | 1 | 2024 | 2548 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2008 | 3358 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2016 | 5672 | 0.100 |
Why?
|
| Monte Carlo Method | 2 | 2008 | 1258 | 0.100 |
Why?
|
| Forecasting | 2 | 2017 | 2928 | 0.100 |
Why?
|
| Models, Econometric | 2 | 2010 | 216 | 0.100 |
Why?
|
| Analgesics, Opioid | 3 | 2023 | 3808 | 0.100 |
Why?
|
| Poisson Distribution | 2 | 2011 | 504 | 0.100 |
Why?
|
| Inflammation | 1 | 2012 | 10774 | 0.100 |
Why?
|
| Guaiac | 2 | 2023 | 13 | 0.100 |
Why?
|
| European Union | 2 | 2014 | 157 | 0.100 |
Why?
|
| Epigenomics | 1 | 2018 | 943 | 0.100 |
Why?
|
| Cardiology | 1 | 2023 | 1656 | 0.100 |
Why?
|
| Protein Precursors | 2 | 2006 | 1132 | 0.100 |
Why?
|
| World Health Organization | 3 | 2020 | 1322 | 0.100 |
Why?
|
| Foot Injuries | 1 | 2013 | 149 | 0.100 |
Why?
|
| Spectrophotometry, Atomic | 1 | 2011 | 82 | 0.100 |
Why?
|
| Legislation, Drug | 1 | 2014 | 214 | 0.100 |
Why?
|
| Neuropsychological Tests | 5 | 2017 | 7054 | 0.100 |
Why?
|
| Substance Abuse, Intravenous | 2 | 2006 | 529 | 0.100 |
Why?
|
| Intestinal Volvulus | 1 | 2012 | 82 | 0.100 |
Why?
|
| Sex Distribution | 3 | 2016 | 2280 | 0.100 |
Why?
|
| Conservation of Natural Resources | 1 | 2014 | 211 | 0.100 |
Why?
|
| Immunization | 1 | 2016 | 1227 | 0.100 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2006 | 488 | 0.100 |
Why?
|
| Disclosure | 1 | 2017 | 748 | 0.090 |
Why?
|
| Erectile Dysfunction | 1 | 2015 | 444 | 0.090 |
Why?
|
| Wound Infection | 1 | 2013 | 246 | 0.090 |
Why?
|
| Health Services for the Aged | 1 | 2013 | 259 | 0.090 |
Why?
|
| Immunization, Secondary | 1 | 2013 | 367 | 0.090 |
Why?
|
| Dietary Supplements | 2 | 2022 | 3415 | 0.090 |
Why?
|
| Communicable Diseases | 1 | 2019 | 875 | 0.090 |
Why?
|
| Anti-HIV Agents | 2 | 2004 | 4527 | 0.090 |
Why?
|
| Influenza, Human | 1 | 2022 | 1521 | 0.090 |
Why?
|
| Rectal Neoplasms | 1 | 2019 | 1157 | 0.090 |
Why?
|
| Patient Discharge | 1 | 2024 | 3443 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 1 | 2003 | 4415 | 0.090 |
Why?
|
| Age Distribution | 3 | 2016 | 2879 | 0.090 |
Why?
|
| Immunosuppressive Agents | 5 | 2004 | 4176 | 0.090 |
Why?
|
| Urinary Incontinence | 1 | 2015 | 489 | 0.090 |
Why?
|
| Ecosystem | 3 | 2021 | 490 | 0.090 |
Why?
|
| Child | 9 | 2020 | 80158 | 0.090 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 728 | 0.090 |
Why?
|
| Disease Susceptibility | 1 | 2017 | 1787 | 0.090 |
Why?
|
| Plasma Cells | 1 | 2013 | 599 | 0.090 |
Why?
|
| Pandemics | 2 | 2020 | 8656 | 0.090 |
Why?
|
| Wound Healing | 1 | 2021 | 2805 | 0.090 |
Why?
|
| Glucose Metabolism Disorders | 1 | 2010 | 52 | 0.090 |
Why?
|
| Volatilization | 1 | 2009 | 77 | 0.090 |
Why?
|
| Coumarins | 1 | 2010 | 118 | 0.090 |
Why?
|
| United States Food and Drug Administration | 1 | 2018 | 1664 | 0.090 |
Why?
|
| Cost Sharing | 1 | 2013 | 409 | 0.080 |
Why?
|
| Cyclosporine | 2 | 2004 | 778 | 0.080 |
Why?
|
| Interviews as Topic | 1 | 2017 | 2696 | 0.080 |
Why?
|
| Breast Feeding | 2 | 2008 | 1360 | 0.080 |
Why?
|
| Geologic Sediments | 1 | 2009 | 80 | 0.080 |
Why?
|
| Confidence Intervals | 2 | 2008 | 2927 | 0.080 |
Why?
|
| Receptors, Estrogen | 1 | 2017 | 2209 | 0.080 |
Why?
|
| Anesthesiology | 1 | 1999 | 1120 | 0.080 |
Why?
|
| Multiple System Atrophy | 1 | 2010 | 130 | 0.080 |
Why?
|
| Disability Evaluation | 3 | 2007 | 1836 | 0.080 |
Why?
|
| Pneumonia | 1 | 2001 | 2143 | 0.080 |
Why?
|
| Adenosine | 2 | 2004 | 808 | 0.080 |
Why?
|
| Dementia | 1 | 2023 | 2689 | 0.080 |
Why?
|
| Medicaid | 1 | 2002 | 2818 | 0.080 |
Why?
|
| Tomography, Optical Coherence | 3 | 2007 | 2917 | 0.080 |
Why?
|
| Health Resources | 2 | 2013 | 935 | 0.080 |
Why?
|
| Primary Health Care | 3 | 2011 | 4687 | 0.080 |
Why?
|
| Feeding Behavior | 1 | 2021 | 3188 | 0.080 |
Why?
|
| Protease Inhibitors | 1 | 2012 | 754 | 0.080 |
Why?
|
| Biopsy | 2 | 2017 | 6766 | 0.080 |
Why?
|
| Czech Republic | 1 | 2008 | 74 | 0.080 |
Why?
|
| Long-Term Care | 2 | 2011 | 633 | 0.080 |
Why?
|
| Animals | 13 | 2023 | 168475 | 0.080 |
Why?
|
| Carboplatin | 1 | 2011 | 794 | 0.080 |
Why?
|
| Tissue Engineering | 1 | 2018 | 1868 | 0.080 |
Why?
|
| Sex Factors | 5 | 2020 | 10554 | 0.080 |
Why?
|
| Beta Particles | 2 | 2005 | 51 | 0.080 |
Why?
|
| Intensive Care Units | 3 | 2022 | 3744 | 0.080 |
Why?
|
| Terminal Care | 1 | 2020 | 1761 | 0.080 |
Why?
|
| Communicable Disease Control | 1 | 2014 | 846 | 0.080 |
Why?
|
| DNA Methylation | 2 | 2022 | 4399 | 0.070 |
Why?
|
| Sirolimus | 2 | 2005 | 1533 | 0.070 |
Why?
|
| United States | 9 | 2021 | 72340 | 0.070 |
Why?
|
| Anticoagulants | 3 | 2014 | 4812 | 0.070 |
Why?
|
| Colonic Neoplasms | 1 | 2019 | 2539 | 0.070 |
Why?
|
| Diagnosis, Differential | 3 | 2018 | 12973 | 0.070 |
Why?
|
| Antibodies, Bacterial | 1 | 2013 | 1469 | 0.070 |
Why?
|
| Double-Blind Method | 4 | 2022 | 12341 | 0.070 |
Why?
|
| Levodopa | 2 | 2010 | 221 | 0.070 |
Why?
|
| Community Networks | 1 | 2009 | 201 | 0.070 |
Why?
|
| Climate Change | 1 | 2014 | 501 | 0.070 |
Why?
|
| Multiple Myeloma | 2 | 2016 | 5146 | 0.070 |
Why?
|
| Penicillamine | 1 | 2007 | 60 | 0.070 |
Why?
|
| HIV Infections | 3 | 2023 | 17354 | 0.070 |
Why?
|
| Medical Record Linkage | 1 | 2009 | 285 | 0.070 |
Why?
|
| Papillomaviridae | 2 | 2022 | 1119 | 0.070 |
Why?
|
| Vaccines | 1 | 2016 | 844 | 0.070 |
Why?
|
| Tacrolimus | 2 | 2002 | 733 | 0.070 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2009 | 148 | 0.070 |
Why?
|
| Aortic Rupture | 1 | 2010 | 319 | 0.070 |
Why?
|
| Heart Function Tests | 1 | 2008 | 318 | 0.070 |
Why?
|
| Osteoporotic Fractures | 1 | 2012 | 411 | 0.070 |
Why?
|
| Diagnostic Techniques, Digestive System | 1 | 2007 | 46 | 0.070 |
Why?
|
| Immunologic Memory | 1 | 2013 | 1359 | 0.070 |
Why?
|
| Hepatolenticular Degeneration | 1 | 2007 | 72 | 0.070 |
Why?
|
| Receptor, erbB-2 | 1 | 2017 | 2557 | 0.070 |
Why?
|
| Prostatectomy | 1 | 2015 | 1824 | 0.070 |
Why?
|
| ROC Curve | 3 | 2009 | 3578 | 0.070 |
Why?
|
| Parkinsonian Disorders | 2 | 2010 | 284 | 0.070 |
Why?
|
| Epilepsy | 1 | 2022 | 3290 | 0.070 |
Why?
|
| Seafood | 1 | 2009 | 393 | 0.070 |
Why?
|
| Acute Coronary Syndrome | 2 | 2009 | 2190 | 0.070 |
Why?
|
| Fishes | 1 | 2009 | 603 | 0.070 |
Why?
|
| Postoperative Complications | 5 | 2023 | 15633 | 0.070 |
Why?
|
| Drug Costs | 3 | 2019 | 1183 | 0.070 |
Why?
|
| Patient Care | 1 | 2012 | 622 | 0.070 |
Why?
|
| Family | 1 | 2017 | 3195 | 0.070 |
Why?
|
| Coated Materials, Biocompatible | 2 | 2007 | 311 | 0.070 |
Why?
|
| Prostate-Specific Antigen | 2 | 2017 | 2469 | 0.070 |
Why?
|
| Bone Marrow Transplantation | 1 | 2014 | 2693 | 0.070 |
Why?
|
| Leg | 3 | 2006 | 1088 | 0.070 |
Why?
|
| Appointments and Schedules | 1 | 2010 | 443 | 0.070 |
Why?
|
| Infant, Low Birth Weight | 1 | 2011 | 870 | 0.060 |
Why?
|
| Deoxycytidine | 1 | 2010 | 877 | 0.060 |
Why?
|
| Emigration and Immigration | 1 | 2009 | 397 | 0.060 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3086 | 0.060 |
Why?
|
| Interferons | 1 | 2009 | 706 | 0.060 |
Why?
|
| Chelating Agents | 1 | 2007 | 387 | 0.060 |
Why?
|
| Stem Cell Transplantation | 1 | 2014 | 1600 | 0.060 |
Why?
|
| Angina Pectoris | 1 | 2009 | 959 | 0.060 |
Why?
|
| Length of Stay | 6 | 2012 | 6426 | 0.060 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 3617 | 0.060 |
Why?
|
| North Sea | 2 | 2003 | 4 | 0.060 |
Why?
|
| Waiting Lists | 1 | 2010 | 765 | 0.060 |
Why?
|
| Observer Variation | 5 | 2006 | 2606 | 0.060 |
Why?
|
| Cause of Death | 3 | 2016 | 3683 | 0.060 |
Why?
|
| Review Literature as Topic | 2 | 2023 | 348 | 0.060 |
Why?
|
| Hemophilia B | 1 | 2005 | 84 | 0.060 |
Why?
|
| Developing Countries | 3 | 2014 | 2885 | 0.060 |
Why?
|
| Internal Mammary-Coronary Artery Anastomosis | 1 | 2004 | 38 | 0.060 |
Why?
|
| Arctic Regions | 2 | 2020 | 26 | 0.060 |
Why?
|
| Research Report | 2 | 2022 | 367 | 0.060 |
Why?
|
| Epidemiologic Methods | 1 | 2009 | 1336 | 0.060 |
Why?
|
| Area Under Curve | 1 | 2009 | 1638 | 0.060 |
Why?
|
| Hearing Disorders | 1 | 2005 | 126 | 0.060 |
Why?
|
| Psychoses, Substance-Induced | 1 | 2005 | 99 | 0.060 |
Why?
|
| Genotype | 3 | 2012 | 12990 | 0.060 |
Why?
|
| Jordan | 1 | 2024 | 73 | 0.060 |
Why?
|
| Drug Therapy | 2 | 2020 | 503 | 0.060 |
Why?
|
| Chi-Square Distribution | 4 | 2015 | 3415 | 0.060 |
Why?
|
| Self-Examination | 1 | 2004 | 71 | 0.060 |
Why?
|
| Travel | 2 | 2020 | 796 | 0.060 |
Why?
|
| Actuarial Analysis | 1 | 2004 | 372 | 0.060 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2020 | 3615 | 0.060 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2009 | 746 | 0.060 |
Why?
|
| Paclitaxel | 1 | 2011 | 1732 | 0.060 |
Why?
|
| Parapoxvirus | 1 | 2003 | 2 | 0.060 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2004 | 198 | 0.060 |
Why?
|
| Poxviridae Infections | 1 | 2003 | 12 | 0.060 |
Why?
|
| Ergolines | 1 | 2003 | 57 | 0.060 |
Why?
|
| Oxygen | 1 | 2015 | 4227 | 0.050 |
Why?
|
| Electronic Health Records | 1 | 2021 | 4811 | 0.050 |
Why?
|
| Patient Care Team | 1 | 2014 | 2521 | 0.050 |
Why?
|
| Metallurgy | 2 | 2017 | 95 | 0.050 |
Why?
|
| Self Report | 1 | 2015 | 3725 | 0.050 |
Why?
|
| Calcitriol | 2 | 2002 | 296 | 0.050 |
Why?
|
| Finland | 1 | 2024 | 607 | 0.050 |
Why?
|
| Mycoplasma genitalium | 1 | 2023 | 12 | 0.050 |
Why?
|
| Software | 2 | 2015 | 4434 | 0.050 |
Why?
|
| Hospital Units | 1 | 2004 | 142 | 0.050 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2003 | 79 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2024 | 12149 | 0.050 |
Why?
|
| Dolphins | 1 | 2002 | 14 | 0.050 |
Why?
|
| Vasodilator Agents | 2 | 2006 | 973 | 0.050 |
Why?
|
| Whales | 1 | 2002 | 30 | 0.050 |
Why?
|
| Prospective Payment System | 1 | 2003 | 136 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2013 | 3492 | 0.050 |
Why?
|
| Veins | 1 | 2007 | 768 | 0.050 |
Why?
|
| Hospital Mortality | 2 | 2022 | 5293 | 0.050 |
Why?
|
| Polysomnography | 1 | 2009 | 1848 | 0.050 |
Why?
|
| Social Work | 1 | 2024 | 159 | 0.050 |
Why?
|
| Utilization Review | 1 | 2004 | 382 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2017 | 12794 | 0.050 |
Why?
|
| Linear Models | 2 | 2021 | 5872 | 0.050 |
Why?
|
| Oregon | 1 | 2002 | 148 | 0.050 |
Why?
|
| Peptides, Cyclic | 1 | 2004 | 392 | 0.050 |
Why?
|
| Mycophenolic Acid | 1 | 2004 | 349 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2018 | 4652 | 0.050 |
Why?
|
| Chest Pain | 2 | 2006 | 1091 | 0.050 |
Why?
|
| Healthy Worker Effect | 1 | 2001 | 29 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3206 | 0.050 |
Why?
|
| Program Development | 1 | 2008 | 1297 | 0.050 |
Why?
|
| Hemophilia A | 1 | 2005 | 360 | 0.050 |
Why?
|
| Odds Ratio | 3 | 2013 | 9647 | 0.050 |
Why?
|
| Insurance Coverage | 1 | 2013 | 1940 | 0.050 |
Why?
|
| Macrolides | 1 | 2023 | 205 | 0.050 |
Why?
|
| Femur Neck | 1 | 2003 | 314 | 0.050 |
Why?
|
| Hemiplegia | 1 | 2022 | 136 | 0.050 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2008 | 1086 | 0.050 |
Why?
|
| Paraplegia | 1 | 2022 | 161 | 0.050 |
Why?
|
| Fentanyl | 1 | 2024 | 434 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2014 | 8633 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 8554 | 0.050 |
Why?
|
| Hemodynamics | 3 | 2008 | 4160 | 0.050 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2003 | 415 | 0.050 |
Why?
|
| Primary Prevention | 1 | 2009 | 1186 | 0.050 |
Why?
|
| Calcinosis | 2 | 2009 | 1469 | 0.050 |
Why?
|
| Patient Readmission | 2 | 2024 | 3271 | 0.050 |
Why?
|
| Bone Density | 3 | 2003 | 3551 | 0.050 |
Why?
|
| Models, Biological | 1 | 2017 | 9469 | 0.050 |
Why?
|
| Energy Metabolism | 1 | 2012 | 2882 | 0.050 |
Why?
|
| Zambia | 1 | 2021 | 262 | 0.050 |
Why?
|
| Thiazolidinediones | 1 | 2004 | 461 | 0.040 |
Why?
|
| Deafness | 1 | 2005 | 459 | 0.040 |
Why?
|
| Echocardiography | 2 | 2006 | 4989 | 0.040 |
Why?
|
| Strontium Radioisotopes | 3 | 2005 | 18 | 0.040 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2004 | 748 | 0.040 |
Why?
|
| Models, Animal | 1 | 2007 | 2112 | 0.040 |
Why?
|
| Torque | 1 | 2020 | 133 | 0.040 |
Why?
|
| Neonatal Screening | 1 | 2005 | 597 | 0.040 |
Why?
|
| Retirement | 1 | 2001 | 198 | 0.040 |
Why?
|
| Diagnosis-Related Groups | 1 | 2001 | 449 | 0.040 |
Why?
|
| Hostility | 1 | 2000 | 183 | 0.040 |
Why?
|
| Stroke Volume | 2 | 2024 | 5496 | 0.040 |
Why?
|
| Laser Therapy | 1 | 2007 | 1092 | 0.040 |
Why?
|
| Cost Control | 1 | 2002 | 628 | 0.040 |
Why?
|
| Atherosclerosis | 2 | 2006 | 3407 | 0.040 |
Why?
|
| Liver Transplantation | 2 | 2009 | 2330 | 0.040 |
Why?
|
| Lipids | 1 | 2011 | 3341 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2007 | 1948 | 0.040 |
Why?
|
| Peripheral Arterial Disease | 1 | 2011 | 1273 | 0.040 |
Why?
|
| Sprains and Strains | 1 | 2000 | 75 | 0.040 |
Why?
|
| Ischemia | 2 | 2005 | 1884 | 0.040 |
Why?
|
| Patient Rights | 1 | 2020 | 125 | 0.040 |
Why?
|
| Neck Muscles | 1 | 2000 | 100 | 0.040 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2020 | 137 | 0.040 |
Why?
|
| Troponin T | 1 | 2004 | 780 | 0.040 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2020 | 128 | 0.040 |
Why?
|
| Vaccination | 2 | 2022 | 3384 | 0.040 |
Why?
|
| Career Mobility | 1 | 2001 | 259 | 0.040 |
Why?
|
| Resource Allocation | 1 | 2002 | 350 | 0.040 |
Why?
|
| Critical Illness | 2 | 2010 | 2723 | 0.040 |
Why?
|
| Coronary Artery Bypass | 3 | 2007 | 2188 | 0.040 |
Why?
|
| Triage | 1 | 2006 | 986 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2008 | 6228 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2011 | 2321 | 0.040 |
Why?
|
| Yttrium Radioisotopes | 3 | 2005 | 107 | 0.040 |
Why?
|
| Indicators and Reagents | 1 | 2019 | 462 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2007 | 20568 | 0.040 |
Why?
|
| Logistic Models | 4 | 2024 | 13255 | 0.040 |
Why?
|
| Nonlinear Dynamics | 1 | 2021 | 492 | 0.040 |
Why?
|
| Patient Selection | 2 | 2008 | 4244 | 0.040 |
Why?
|
| Blood Flow Velocity | 1 | 2002 | 1371 | 0.040 |
Why?
|
| Geographic Information Systems | 1 | 2021 | 281 | 0.040 |
Why?
|
| International Cooperation | 2 | 2016 | 1422 | 0.040 |
Why?
|
| Premature Birth | 1 | 2011 | 1782 | 0.040 |
Why?
|
| Mutation | 1 | 2023 | 30053 | 0.040 |
Why?
|
| Femoral Artery | 1 | 2003 | 826 | 0.040 |
Why?
|
| Health Personnel | 1 | 2012 | 3335 | 0.040 |
Why?
|
| Arteriosclerosis | 1 | 2003 | 1055 | 0.040 |
Why?
|
| Creatine Kinase | 1 | 2020 | 685 | 0.040 |
Why?
|
| Advance Directives | 1 | 2020 | 249 | 0.040 |
Why?
|
| Water Pollutants, Chemical | 1 | 2002 | 359 | 0.040 |
Why?
|
| Anger | 1 | 2000 | 406 | 0.040 |
Why?
|
| Muscles | 1 | 2023 | 1576 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2023 | 1334 | 0.040 |
Why?
|
| Blood Glucose | 2 | 2024 | 6391 | 0.040 |
Why?
|
| Hyperemia | 3 | 2004 | 221 | 0.040 |
Why?
|
| DNA, Neoplasm | 1 | 2023 | 1745 | 0.040 |
Why?
|
| Hospital Costs | 1 | 2004 | 947 | 0.040 |
Why?
|
| Ticlopidine | 1 | 2022 | 730 | 0.040 |
Why?
|
| Aging | 1 | 2016 | 8710 | 0.040 |
Why?
|
| South Africa | 1 | 2023 | 1843 | 0.040 |
Why?
|
| Morals | 1 | 2020 | 289 | 0.040 |
Why?
|
| Health Care Surveys | 2 | 2020 | 2426 | 0.040 |
Why?
|
| Femur | 1 | 2003 | 1307 | 0.030 |
Why?
|
| Autopsy | 1 | 2001 | 1009 | 0.030 |
Why?
|
| Hepatectomy | 1 | 2020 | 557 | 0.030 |
Why?
|
| Calibration | 1 | 2019 | 818 | 0.030 |
Why?
|
| Public Health Practice | 1 | 2019 | 219 | 0.030 |
Why?
|
| Air Pollutants | 1 | 2010 | 2896 | 0.030 |
Why?
|
| Pregnancy | 3 | 2011 | 29890 | 0.030 |
Why?
|
| Brain | 1 | 2003 | 27121 | 0.030 |
Why?
|
| Lower Extremity | 1 | 2004 | 1202 | 0.030 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2005 | 2118 | 0.030 |
Why?
|
| Retreatment | 2 | 2009 | 598 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2009 | 3359 | 0.030 |
Why?
|
| Vasodilation | 3 | 2006 | 962 | 0.030 |
Why?
|
| Referral and Consultation | 2 | 2013 | 3600 | 0.030 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2009 | 2223 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 10194 | 0.030 |
Why?
|
| Physical Fitness | 1 | 2020 | 743 | 0.030 |
Why?
|
| Child, Preschool | 4 | 2016 | 42232 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2006 | 2220 | 0.030 |
Why?
|
| Pyrroles | 1 | 2002 | 1125 | 0.030 |
Why?
|
| Choice Behavior | 1 | 2022 | 825 | 0.030 |
Why?
|
| Hypertension | 3 | 2021 | 8540 | 0.030 |
Why?
|
| Alzheimer Disease | 1 | 2017 | 8601 | 0.030 |
Why?
|
| Drug Implants | 2 | 2007 | 230 | 0.030 |
Why?
|
| Health Promotion | 1 | 2008 | 2214 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2005 | 2650 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2004 | 2118 | 0.030 |
Why?
|
| Blood Pressure | 4 | 2005 | 8481 | 0.030 |
Why?
|
| Mediastinum | 1 | 2017 | 266 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 17904 | 0.030 |
Why?
|
| Comprehension | 1 | 2021 | 621 | 0.030 |
Why?
|
| Longitudinal Studies | 4 | 2021 | 14608 | 0.030 |
Why?
|
| Mood Disorders | 1 | 2022 | 1127 | 0.030 |
Why?
|
| Recurrence | 4 | 2016 | 8466 | 0.030 |
Why?
|
| Japan | 1 | 2019 | 1378 | 0.030 |
Why?
|
| Exercise Therapy | 1 | 2022 | 929 | 0.030 |
Why?
|
| Epidemics | 1 | 2021 | 512 | 0.030 |
Why?
|
| Neoplasm Metastasis | 2 | 2017 | 4915 | 0.030 |
Why?
|
| Attitude | 1 | 2020 | 775 | 0.030 |
Why?
|
| Ataxia | 1 | 2017 | 306 | 0.030 |
Why?
|
| Immunity | 1 | 2020 | 996 | 0.030 |
Why?
|
| Antarctic Regions | 1 | 2014 | 13 | 0.030 |
Why?
|
| Ice Cover | 1 | 2014 | 8 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2005 | 2884 | 0.030 |
Why?
|
| Preventive Medicine | 1 | 2016 | 246 | 0.030 |
Why?
|
| Egypt | 1 | 2014 | 97 | 0.030 |
Why?
|
| Catheter Ablation | 1 | 2007 | 2751 | 0.030 |
Why?
|
| Population Density | 1 | 2014 | 193 | 0.030 |
Why?
|
| Health Surveys | 1 | 2003 | 4061 | 0.030 |
Why?
|
| Lymph Nodes | 2 | 2017 | 3465 | 0.030 |
Why?
|
| Biological Availability | 1 | 2014 | 390 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2021 | 2330 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2004 | 5485 | 0.030 |
Why?
|
| Endosonography | 1 | 2017 | 609 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2010 | 2850 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2024 | 2176 | 0.030 |
Why?
|
| Pediatrics | 1 | 2008 | 3589 | 0.030 |
Why?
|
| Calcium | 1 | 2006 | 5722 | 0.030 |
Why?
|
| Planning Techniques | 1 | 2012 | 82 | 0.030 |
Why?
|
| Contrast Media | 4 | 2007 | 5307 | 0.030 |
Why?
|
| Maximal Voluntary Ventilation | 1 | 2012 | 14 | 0.030 |
Why?
|
| Pensions | 1 | 2012 | 16 | 0.030 |
Why?
|
| Ascitic Fluid | 1 | 2012 | 189 | 0.030 |
Why?
|
| Demography | 2 | 2007 | 1648 | 0.030 |
Why?
|
| Anorexia | 1 | 2012 | 154 | 0.020 |
Why?
|
| Mesentery | 1 | 2012 | 202 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 1999 | 1141 | 0.020 |
Why?
|
| Forearm Injuries | 1 | 2012 | 68 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2004 | 2472 | 0.020 |
Why?
|
| Population Dynamics | 1 | 2014 | 307 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2004 | 4431 | 0.020 |
Why?
|
| Home Nursing | 1 | 2012 | 92 | 0.020 |
Why?
|
| Malaria | 1 | 2021 | 1227 | 0.020 |
Why?
|
| Schools | 1 | 2020 | 1489 | 0.020 |
Why?
|
| Tissue Donors | 2 | 1999 | 2332 | 0.020 |
Why?
|
| Fear | 1 | 2020 | 1477 | 0.020 |
Why?
|
| Enteritis | 1 | 2012 | 162 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2002 | 2568 | 0.020 |
Why?
|
| Cognition Disorders | 2 | 2020 | 3980 | 0.020 |
Why?
|
| Vascular Patency | 2 | 2004 | 911 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2021 | 2979 | 0.020 |
Why?
|
| Shy-Drager Syndrome | 1 | 2010 | 9 | 0.020 |
Why?
|
| Glaucoma | 1 | 2021 | 1185 | 0.020 |
Why?
|
| Lung Volume Measurements | 1 | 2012 | 375 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2004 | 3085 | 0.020 |
Why?
|
| Health Planning | 1 | 2012 | 230 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 36426 | 0.020 |
Why?
|
| Mongolia | 1 | 2010 | 93 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 2024 | 3879 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2016 | 2115 | 0.020 |
Why?
|
| Plant Lectins | 1 | 1991 | 103 | 0.020 |
Why?
|
| Hypothyroidism | 1 | 2016 | 668 | 0.020 |
Why?
|
| Rib Fractures | 1 | 2012 | 128 | 0.020 |
Why?
|
| Aspirin | 1 | 2022 | 3133 | 0.020 |
Why?
|
| Social Support | 1 | 2000 | 2172 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2021 | 2690 | 0.020 |
Why?
|
| Thalidomide | 1 | 2016 | 885 | 0.020 |
Why?
|
| Health Services Accessibility | 2 | 2012 | 5440 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2022 | 2751 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2002 | 3313 | 0.020 |
Why?
|
| Syndrome | 2 | 2007 | 3267 | 0.020 |
Why?
|
| Disaccharides | 1 | 1991 | 170 | 0.020 |
Why?
|
| Lymphocytes | 2 | 2004 | 2612 | 0.020 |
Why?
|
| Osteoporosis | 1 | 1999 | 1606 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2011 | 6484 | 0.020 |
Why?
|
| Substance P | 1 | 1991 | 335 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 2 | 2007 | 1702 | 0.020 |
Why?
|
| Physical Endurance | 1 | 2012 | 366 | 0.020 |
Why?
|
| Access to Information | 1 | 2012 | 316 | 0.020 |
Why?
|
| Cerebellar Ataxia | 1 | 2010 | 150 | 0.020 |
Why?
|
| Vital Capacity | 1 | 2012 | 971 | 0.020 |
Why?
|
| Prostate | 1 | 2017 | 1773 | 0.020 |
Why?
|
| Microcirculation | 2 | 2004 | 1272 | 0.020 |
Why?
|
| Seizures | 1 | 2022 | 2957 | 0.020 |
Why?
|
| Humeral Fractures | 1 | 2012 | 282 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2004 | 3763 | 0.020 |
Why?
|
| Cytokines | 1 | 2004 | 7396 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2015 | 2358 | 0.020 |
Why?
|
| Risk | 2 | 2017 | 9610 | 0.020 |
Why?
|
| Fractures, Bone | 1 | 2020 | 2046 | 0.020 |
Why?
|
| Vitamin D | 1 | 2022 | 3303 | 0.020 |
Why?
|
| Inhalation Exposure | 1 | 2010 | 432 | 0.020 |
Why?
|
| Observation | 1 | 2009 | 310 | 0.020 |
Why?
|
| Hypotension, Orthostatic | 1 | 2010 | 258 | 0.020 |
Why?
|
| Ceruloplasmin | 1 | 2007 | 56 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2001 | 11076 | 0.020 |
Why?
|
| Forced Expiratory Volume | 1 | 2012 | 1814 | 0.020 |
Why?
|
| DNA, Viral | 2 | 2004 | 2202 | 0.020 |
Why?
|
| Aminophylline | 1 | 2006 | 41 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2021 | 3802 | 0.020 |
Why?
|
| Telemedicine | 1 | 2024 | 3052 | 0.020 |
Why?
|
| Dipyridamole | 1 | 2006 | 140 | 0.020 |
Why?
|
| Reference Values | 2 | 2005 | 4920 | 0.020 |
Why?
|
| Interprofessional Relations | 1 | 2012 | 990 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 4016 | 0.020 |
Why?
|
| Hemorrhage | 2 | 2010 | 3424 | 0.020 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2006 | 166 | 0.020 |
Why?
|
| Technology, High-Cost | 1 | 2005 | 32 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2010 | 10766 | 0.020 |
Why?
|
| Warfarin | 1 | 2014 | 1483 | 0.020 |
Why?
|
| Home Care Services | 1 | 2012 | 648 | 0.020 |
Why?
|
| Spinal Fractures | 1 | 2012 | 705 | 0.020 |
Why?
|
| Myocardial Ischemia | 2 | 2006 | 2113 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2010 | 1156 | 0.020 |
Why?
|
| Radiotherapy Dosage | 2 | 2002 | 2898 | 0.020 |
Why?
|
| Necrosis | 1 | 2009 | 1611 | 0.020 |
Why?
|
| Genome, Human | 1 | 2018 | 4425 | 0.010 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2006 | 148 | 0.010 |
Why?
|
| Hindlimb | 1 | 2007 | 513 | 0.010 |
Why?
|
| Pokeweed Mitogens | 1 | 2004 | 38 | 0.010 |
Why?
|
| Copper | 1 | 2007 | 369 | 0.010 |
Why?
|
| Prisons | 1 | 2006 | 174 | 0.010 |
Why?
|
| Phytohemagglutinins | 1 | 2004 | 167 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 7406 | 0.010 |
Why?
|
| Concanavalin A | 1 | 2004 | 190 | 0.010 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2004 | 158 | 0.010 |
Why?
|
| Rheumatoid Factor | 1 | 2004 | 185 | 0.010 |
Why?
|
| Feasibility Studies | 2 | 2005 | 5247 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 1991 | 1889 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 2005 | 573 | 0.010 |
Why?
|
| Sleep, REM | 1 | 2007 | 595 | 0.010 |
Why?
|
| Family Practice | 1 | 2006 | 512 | 0.010 |
Why?
|
| Hip Fractures | 1 | 2012 | 988 | 0.010 |
Why?
|
| Age of Onset | 1 | 2010 | 3306 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2021 | 12953 | 0.010 |
Why?
|
| Injections, Intra-Arterial | 1 | 2003 | 182 | 0.010 |
Why?
|
| Intestines | 1 | 2012 | 1910 | 0.010 |
Why?
|
| Factor VIII | 1 | 2005 | 348 | 0.010 |
Why?
|
| Movement Disorders | 1 | 2007 | 459 | 0.010 |
Why?
|
| Cardiotonic Agents | 1 | 2006 | 539 | 0.010 |
Why?
|
| Gadolinium DTPA | 1 | 2006 | 823 | 0.010 |
Why?
|
| Pacific Ocean | 1 | 2002 | 15 | 0.010 |
Why?
|
| Halogens | 1 | 2002 | 13 | 0.010 |
Why?
|
| Terminology as Topic | 1 | 2010 | 1530 | 0.010 |
Why?
|
| Water Movements | 1 | 2002 | 17 | 0.010 |
Why?
|
| Time | 1 | 2004 | 546 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2005 | 957 | 0.010 |
Why?
|
| Albumins | 1 | 2005 | 575 | 0.010 |
Why?
|
| Fibrosis | 1 | 2009 | 2049 | 0.010 |
Why?
|
| Equipment Failure | 1 | 2004 | 578 | 0.010 |
Why?
|
| Perfusion | 1 | 2007 | 1373 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2005 | 1152 | 0.010 |
Why?
|
| Asthma | 1 | 2021 | 6234 | 0.010 |
Why?
|
| Epidemiologic Studies | 1 | 2005 | 675 | 0.010 |
Why?
|
| Angioplasty, Balloon | 1 | 2005 | 589 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 2169 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2004 | 1991 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 2010 | 2382 | 0.010 |
Why?
|
| Temperature | 1 | 2007 | 2226 | 0.010 |
Why?
|
| Fibromuscular Dysplasia | 1 | 2000 | 55 | 0.010 |
Why?
|
| Hepatitis B | 1 | 2005 | 705 | 0.010 |
Why?
|
| Mucous Membrane | 1 | 2003 | 659 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 2005 | 1515 | 0.010 |
Why?
|
| Caregivers | 1 | 2012 | 2238 | 0.010 |
Why?
|
| Fluorocarbons | 1 | 2005 | 492 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2004 | 2217 | 0.010 |
Why?
|
| Communication | 1 | 2014 | 3875 | 0.010 |
Why?
|
| DNA Primers | 1 | 2004 | 2820 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 2004 | 1526 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2004 | 1814 | 0.010 |
Why?
|
| Life Style | 1 | 2011 | 3917 | 0.010 |
Why?
|
| Dobutamine | 1 | 1999 | 116 | 0.010 |
Why?
|
| Emergencies | 1 | 2006 | 1217 | 0.010 |
Why?
|
| Interleukins | 1 | 2004 | 782 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2007 | 4111 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2014 | 3816 | 0.010 |
Why?
|
| Body Height | 1 | 2004 | 1570 | 0.010 |
Why?
|
| Bone Resorption | 1 | 2002 | 723 | 0.010 |
Why?
|
| Safety | 1 | 2002 | 1149 | 0.010 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1999 | 345 | 0.010 |
Why?
|
| Diet | 1 | 2016 | 8075 | 0.010 |
Why?
|
| Placebos | 1 | 2002 | 1667 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2007 | 2095 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2003 | 2571 | 0.010 |
Why?
|
| Internal Medicine | 1 | 2004 | 1051 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 4576 | 0.010 |
Why?
|
| Calcium, Dietary | 1 | 1999 | 529 | 0.010 |
Why?
|
| Obesity | 1 | 1999 | 12947 | 0.010 |
Why?
|
| Ultrasonography | 2 | 2000 | 5971 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2004 | 1964 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 2004 | 17635 | 0.010 |
Why?
|
| Circadian Rhythm | 1 | 2007 | 2576 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2004 | 1958 | 0.010 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 1999 | 851 | 0.010 |
Why?
|
| Viral Load | 1 | 2003 | 3332 | 0.010 |
Why?
|
| Atrial Fibrillation | 1 | 2012 | 5127 | 0.010 |
Why?
|
| Hospitals | 1 | 2007 | 3883 | 0.010 |
Why?
|
| Base Sequence | 1 | 2004 | 12441 | 0.010 |
Why?
|
| Estrogens | 1 | 1999 | 1522 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 4352 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2006 | 6377 | 0.010 |
Why?
|
| Cerebral Hemorrhage | 1 | 2004 | 2656 | 0.010 |
Why?
|
| Equipment Design | 1 | 2000 | 3511 | 0.010 |
Why?
|
| Triglycerides | 1 | 1999 | 2461 | 0.010 |
Why?
|
| Heart Rate | 1 | 2003 | 4195 | 0.010 |
Why?
|
| Boston | 1 | 2004 | 9327 | 0.010 |
Why?
|
| Ribosome Inactivating Proteins | 1 | 1991 | 7 | 0.010 |
Why?
|
| Agglutination | 1 | 1991 | 41 | 0.010 |
Why?
|
| Liver | 1 | 2007 | 7528 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1999 | 4807 | 0.010 |
Why?
|
| Cholesterol | 1 | 1999 | 2905 | 0.010 |
Why?
|
| Carbohydrate Sequence | 1 | 1991 | 411 | 0.010 |
Why?
|
| Brain Ischemia | 1 | 2004 | 3049 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2008 | 22176 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1991 | 866 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2003 | 4062 | 0.010 |
Why?
|
| Lectins | 1 | 1991 | 491 | 0.000 |
Why?
|
| Radiography | 1 | 1999 | 6965 | 0.000 |
Why?
|
| Testosterone | 1 | 1999 | 2472 | 0.000 |
Why?
|
| Glycosylation | 1 | 1991 | 1097 | 0.000 |
Why?
|
| Glycoproteins | 1 | 1991 | 2203 | 0.000 |
Why?
|